FDA Approves Vertex Pharmaceuticals’ Orkambi For Use In Children Aged 12-24 Months

Trending News ☀️

The FDA’s approval of Vertex Pharmaceuticals($NASDAQ:VRTX)’ Orkambi for use in children aged 12-24 months is a significant development for the treatment of cystic fibrosis . CF is a multi-organ disorder caused by a defective and/or missing CFTR protein due to mutations in the cystic fibrosis transmembrane conductance regulator gene. This approval expands the use of Orkambi to a younger population of patients, which is expected to have a positive impact on Vertex’s market and earnings in the long term.

Market Price

This news sent the stock soaring, with it opening at $290.2 and closing at $281.0. This is a big win for the company, as Orkambi is a key part of their business. The approval opens up a new market for the drug and is likely to result in increased sales.

VI Analysis

A company’s fundamentals are a reflection of its long-term potential. The below analysis of VERTEX PHARMACEUTICALS is made simple by VI app. Based on the VI Star Chart, VERTEX PHARMACEUTICALS has a high health score of 8/10 considering its cashflows and debt. This means that the company is capable of sustaining future operations in times of crisis. VERTEX PHARMACEUTICALS is strong in assets, growth, and profitability. However, it is weak in dividend. VERTEX PHARMACEUTICALS is classified as a ‘gorilla’. This is a type of company that has achieved stable and high revenue or earning growth due to its strong competitive advantage. High growth companies are deemed more risky as they attempt to grow faster.

Summary

However, the stock price moved down the same day.